SLC5A2 and type 2 diabetes mellitus: Several studies analyzing the renal effects of SGLT2 inhibitors as secondary outcomes in large cardiovascular outcome trials involving individuals with type 2 diabetes have demonstrated the renal benefits of SGLT2 inhibitors [12–14].